Advertisement

Mohs micrographic surgery versus wide local excision for eyelid melanoma: An analysis of a national database

Published:August 28, 2022DOI:https://doi.org/10.1016/j.bjps.2022.08.076

      Summary

      Background

      Although eyelid melanomas represent less than 1% of eyelid neoplasms, they have the worst prognosis. Wide local excision (WLE) and Mohs micrographic surgery (MMS) are mainstay treatment options. We conducted a retrospective analysis to assess all-cause and cause-specific mortality rates in patients undergoing WLE or MMS for eyelid melanoma.

      Methods

      A retrospective analysis of Surveillance, Epidemiology, and End Results (SEER) registry was performed for eyelid melanoma treated with WLE or MMS. Cases were limited to American Joint Committee on Cancer (AJCC) stage T1 primary malignancies.

      Results

      A total of 45 cases of WLE were identified along with 48 cases of MMS for eyelid melanoma. There was no significant difference between subgroups in age group, sex, race, ethnicity, marital status at diagnosis, AJCC N stage, AJCC M stage, melanoma histology, chemotherapy use, and radiotherapy use. Among the cohort, all tumors were unilateral. Kaplan–Meier analysis with log-rank demonstrated no significant difference between MMS and WLE subgroups with regard to overall survival (P = 0.662) and cancer-specific survival (P = 0.494). Cox regression adjusting for variables with α<0.10 and found no significant difference in all-cause mortality (HR, 0.923; 95% CI 0.310–2.747; P = 0.885) or cancer-specific mortality (HR, 0.518; 95% CI 0.047–5.711; P = 0.591) when patients who underwent MMS were compared to those who underwent WLE.

      Conclusion

      While our study is limited by a small number of patients, our analysis demonstrated no significant difference in all-cause or cause-specific survival for patients with eyelid melanoma treated with MMS compared with WLE. In areas requiring preservation of tissue due to cosmetic or functional purposes, MMS is a reasonable surgical approach.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Plastic, Reconstructive & Aesthetic Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lomas A.
        • Leonardi-Bee J.
        • Bath-Hextall F.
        A systematic review of worldwide incidence of nonmelanoma skin cancer.
        Br J Dermatol. 2012; 166: 1069-1080
        • Stern R.S.
        Prevalence of a history of skin cancer in 2007: results of an incidence-based model.
        Arch Dermatol. 2010; 146: 279-282
        • Burdon-Jones D.
        • Thomas P.
        • Baker R.
        Quality of life issues in nonmetastatic skin cancer.
        Br J Dermatol. 2010; 162: 147-151
        • Connolly K.L.
        • Jeong J.M.
        • Barker C.A.
        • Hernandez M.
        • Lee E.H.
        A systematic review of comorbidity indices used in the nonmelanoma skin cancer population.
        J Am Acad Dermatol. 2017; 76 (344-346.e2)
        • Pollack L.A.
        • Li J.
        • Berkowitz Z.
        • Weir H.K.
        • Wu X.C.
        • Ajani U.A.
        • et al.
        Melanoma survival in the United States, 1992 to 2005.
        J Am Acad Dermatol. 2011; 65 (S78.e01–S78.e10)
      1. Medical Expenditure Panel Survey. Rockville, MD: Agency for Healthcare Research and Quality; [January 2014].

        • United States Cancer Statistics
        1999–2012 Incidence and Mortality Web-Based Report.
        U.S. Cancer Statistics Working Group, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, Atlanta, GA2015
        • Pe'er J.
        Pathology of eyelid tumors.
        Indian J Ophthalmol. 2016; 64: 177-190
        • Bedrossian E.H.
        Embryology and anatomy of the eyelid.
        in: Tasman W Jaeger EA 1. Lippincott Williams & Wilkins, Philadelphia2004: 1-24 (Ch. 5)
        • Bagheri A.
        • Tavakoli M.
        • Kanaani A.
        • et al.
        Eyelid masses: a 10-year survey from a tertiary eye hospital in Tehran.
        Middle East Afr J Ophthalmol. 2013; 20: 187-192
        • Boulos P.R.
        • Rubin P.A.
        Cutaneous melanomas of the eyelid.
        Semin Ophthalmol. Jul-Sep 2006; 21: 195-206
        • Kersten R.C.
        • Ewing-Chow D.
        • Kulwin D.R.
        • Gallon M.
        Accuracy of clinical diagnosis of cutaneous eyelid lesions.
        Ophthalmology. 1997; 104: 479-484
        • Cook Jr, B.E.
        • Bartley G.B.
        Treatment options and future prospects for the management of eyelid malignancies: an evidence-based update.
        Ophthalmology. 2001; 108: 2088-2098
        • Bolshinsky V.
        • Lin M.J.
        • Serpell J.
        • Leung M.
        • Wolfe R.
        • McLean C.
        • et al.
        Frequency of residual melanoma in wide local excision (WLE) specimens after complete excisional biopsy.
        J Am Acad Dermatol. Jan 2016; 74: 102-107
        • Hocevar M.
        • Dragonja Z.
        • Pilko G.
        • Gazic B.
        • Zgajnar J.
        Residual melanoma after an excisional biopsy is an independent prognostic factor for local recurrence and overall survival.
        Eur J Surg Oncol. Oct 2014; 40: 1271-1275
        • Aitken J.F.
        • Barbour A.
        • Burmeister B.
        • Simon T.
        • Walpole E.
        Clinical Practice Guidelines For the Management of Melanoma in Australia and New Zealand.
        Cancer Council Australia; Australian Cancer Network; Ministry of Health, New Zealand2008
        • Cook J.
        • Zitelli J.
        Mohs micrographic surgery: a cost analysis.
        J Am Acad Dermatol. 1998; 39: 698-703
        • Otley C.C.
        • Salasche S.J.
        Mohs surgery: efficient and effective.
        Br J Ophthalmol. 2004; 88: 1228
      2. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Custom Data (with additional treatment fields), Nov 2017 Sub (1973-2015 varying) - Linked To County Attributes - Total U.S., 1969-2016 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2018, based on the November 2017 submission.

        • Phan K.
        • Loya A.
        Mohs micrographic surgery versus wide local excision for melanoma in situ: analysis of a nationwide database.
        Int J Dermatol. 2019; ([Epub ahead of print])
        • Phan K.
        • Loya A.
        Mohs micrographic surgery versus wide local excision for sebaceous adenocarcinoma of the eyelid – analysis of a national database.
        J Plast Reconstr Aes. 2019; ([Epub ahead of print])
        • Chan F.M.
        • O'Donnell B.A.
        • Whitehead K.
        • Ryman W.
        • Sullivan T.J.
        Treatment and outcomes of malignant melanoma of the eyelid: a review of 29 cases in Australia.
        Ophthalmology. Jan 2007; 114: 187-192
        • Liu A.
        • Botkin A.
        • Murray C.
        • Goldstein D.
        • Hofer S.O.P.
        • Solish N.
        • Kitchen J.
        • Chan A.W.
        Treatment for Lentigo Maligna of the head and neck: survey of practices in Ontario, Canada.
        Dermatol Surg. Jul 2018; 44: 918-923
        • Slutsky J.B.
        • Jones E.C.
        Periocular cutaneous malignancies: a review of the literature.
        Dermatol Surg. Apr 2012; 38: 552-569
        • Tildsley J.
        • Diaper C.
        • Herd R.
        Mohs surgery vs primary excision for eyelid BCCs.
        Orbit. Jun 2010; 29: 140-145
        • Nemet A.Y.
        • Deckel Y.
        • Martin P.A.
        • Kourt G.
        • Chilov M.
        • Sharma V.
        • Benger R.
        Management of periocular basal and squamous cell carcinoma: a series of 485 cases.
        Am J Ophthalmol. Aug 2006; 142: 293-297
      3. National Comprehensive Cancer Network version 1. 2019 Cutaneous Melanoma. https://www.nccn.org/store/login/login.aspx?Return URL=https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf?fbclid=IwAR3GyHIxffTkAp_u8F89-b4ftvPes4rPgp2Jt8fqdl4Mk9Xvk6dTqxxAODs. Accessed on: March 5, 2019.

        • Chin-Lenn L.
        • Murynka T.
        • McKinnon J.G.
        • Arlette J.P.
        Comparison of outcomes for malignant melanoma of the face treated using Mohs micrographic surgery and wide local excision.
        Dermatol Surg. Nov 2013; 39: 1637-1645
        • Trofymenko O.
        • Bordeaux J.S.
        • Zeitouni N.C.
        Melanoma of the face and Mohs micrographic surgery: nationwide mortality data analysis.
        Dermatol Surg. Apr 2018; 44: 481-492
        • Zhou C.
        • Wu F.
        • Chai P.
        • Shi Y.
        • Ye J.
        • Shi X.
        • Tan J.
        • Ding Y.
        • Luo Y.
        • Esmaeli B.
        • Jia R.
        • Fan X.
        Mohs micrographic surgery for eyelid sebaceous carcinoma: a multicenter cohort of 360 patients.
        J Am Acad Dermatol. 2019 Jan 9; (pii: S0190-9622(19)30059-3)
        • Balasubramanian A.
        • Kannan N.S.
        Eyelid malignancies- always quite challenging.
        J Clin Diagn Res. 2017; 11: XR01-XR04
        • Seth R.
        • Revenaugh P.C.
        • Vidimos A.T.
        • Scharpf J.
        • Somani A.K.
        • Fritz M.A
        Simultaneous intraoperative Mohs clearance and reconstruction for advanced cutaneous malignancies.
        Arch Facial Plast Surg. 2011; 13: 404-410
        • Sobanko J.F.
        • Sarwer D.B.
        • Zvargulis Z.
        • Miller C.J.
        Importance of physical appearance in patients with skin cancer.
        Dermatol Surg. 2015; 41: 183-188
        • Borah G.L.
        • Rankin M.K.
        Appearance is a function of the face.
        Plast Reconstr Surg. 2010; 125: 873-878
        • Beal B.T.
        • White E.K.
        • Behera A.K.
        • Zavell A.E.
        • McGuinness A.E.
        • Blangger H.
        • et al.
        Patients' body image improves after Mohs micrographic surgery for nonmelanoma head and neck skin cancer.
        Dermatol Surg. Nov 2018; 44: 1380-1388
        • Pearl R.L.
        • Shao K.
        • Shin T.M.
        • Miller C.J.
        • Sobanko J.F.
        Acute appearance concerns in patients undergoing Mohs surgery: a single-institution cross-sectional study.
        Dermatol Surg. Oct 2018; 44: 1349-1351
        • Hewes E.H.
        • Sullivan J.H.
        • Beard C.
        Lower eyelid reconstruction by tarsal transposition.
        Am J Ophthalmol. 1978; 85: 1164-1169
        • Cutler N.L.
        • Beard C.
        A method for partial and total upper lid reconstruction.
        Am J Ophthalmol. 1955; 39: 1-7
        • Tenzel R.R.
        • Stewart W.B.
        Eyelid reconstruction by the semicircle flap technique.
        Ophthalmology. 1978; 85: 1164-1169
        • Harrington J.N.
        Reconstruction of the medial canthus by spontaneous granulation (laissez-faire): a review.
        Annals Ophthalmol. 1982; 14: 956-960
        • Beaulieu D.
        • Fathi R.
        • Srivastava D.
        • Nijhawan R.I.
        Current perspectives on Mohs micrographic surgery for melanoma.
        Clin Cosmet Investig Dermatol. 2018 Jun 20; 11: 309-320
        • Ellison P.M.
        • Zitelli J.A.
        • Brodland D.G.
        Mohs micrographic surgery for melanoma: a prospective multicenter study.
        J Am Acad Dermatol. Sep 2019; 81: 767-774
      4. License for Use of Current Procedural Terminology, Fourth Edition ("CPT®"). Centers for Medicare & Medicaid Services. https://www.cms.gov/medicare/physician-fee-schedule/search?Y=0&T=4&HT=0&CT=3&H1=11643&M=5. Accessed August 24, 2022.

        • Karanetz I.
        • Stanley S.
        • Knobel D.
        • Smith B.D.
        • Bastidas N.
        • Beg M.
        • Kasabian A.K.
        • Tanna N.
        Melanoma extirpation with immediate reconstruction: the oncologic safety and cost savings of single-stage treatment.
        Plast Reconstr Surg. Jul 2016; 138: 256-261
        • Ravitskiy L.
        • Brodland D.G.
        • Zitelli J.A.
        Cost analysis: Mohs micrographic surgery.
        Dermatol Surg. Apr 2012; 38: 585-594
        • Swetter S.M.
        • Tsao H.
        • Bichakjian C.K.
        • Curiel-Lewandrowski C.
        • Elder D.E.
        • Gershenwald J.E.
        • Guild V.
        • Grant-Kels J.M.
        • Halpern A.C.
        • Johnson T.M.
        • Sober A.J.
        • Thompson J.A.
        • Wisco O.J.
        • Wyatt S.
        • Hu S.
        • Lamina T.
        Guidelines of care for the management of primary cutaneous melanoma.
        J Am Acad Dermatol. Jan 2019; 80: 208-250

      Linked Article

      • Managing cutaneous melanoma of the eyelid: Evidence from surveillance, epidemiology, and end results (SEER) program
        Journal of Plastic, Reconstructive & Aesthetic SurgeryVol. 75Issue 12
        • Preview
          Ramachandran and Phan's investigation of Mohs Micrographic Surgery (MMS) versus Wide Local Excision (WLE) for T1 stage eyelid melanoma1 has important implications for plastic surgery. The study, based on analysis of Surveillance, Epidemiology, and End Results (SEER) Program data, found comparable overall survival and cancer-specific survival for MMS and WLE at over 5-years median follow-up. The non-inferiority of MMS is a promising result. Despite significant surgical innovation in periorbital reconstruction,2–4 the eyelid remains a high-risk site for functional and aesthetic impairments after surgery.
        • Full-Text
        • PDF